Microbial consortium and uses thereof
Provided herein are, inter alia, microbial compositions and methods of using the same. The microbial compositions provided include, inter alia, therapeutically effective amounts of Lactobacillus johnsonii, Faecalibacterium prausnitzii, Akkermansia muciniphila, Myxococcus xanthus and Pediococcus pentosaceus and are particularly useful for methods of treating and preventing inflammatory diseases.
1. A method of treating or reducing the incidence of allergic inflammation, the method comprising administering a bacterial population comprising isolates of at least: Lactobacillus sp., Faecalibacterium sp., and Akkermansia muciniphila to a subject in need thereof, wherein the bacterial population is present in an effective amount for treating or reducing the incidence of allergic inflammation in the subject.
2. The method of claim 1 , wherein the Lactobacillus sp. is Lactobacillus johnsonii.
3. The method of claim 1 , wherein the Faecalibacterium sp. is Faecalibacterium prausnitzii.
4. The method of claim 1 , wherein the Lactobacillus sp. is Lactobacillus zeae, Lactobacillus acidipiscis, Lactobacillus acidophilus, Lactobacillus agilis, Lactobacillus aviarius, Lactobacillus brevis, Lactobacillus coleohominis, Lactobacillus crispatus, Lactobacillus crustorum, Lactobacillus curvatus, Lactobacillus diolivorans, Lactobacillus farraginis, Lactobacillus fermentum, Lactobacillus fuchuensis, Lactobacillus harbinensis, Lactobacillus helveticus, Lactobacillus hilgardii, Lactobacillus intestinalis, Lactobacillus jensenii, Lactobacillus kefiranofaciens, Lactobacillus kefiri, Lactobacillus lindneri, Lactobacillus mali, Lactobacillus manihotivorans, Lactobacillus mucosae, Lactobacillus oeni, Lactobacillus oligofermentans, Lactobacillus panis, Lactobacillus pantheris, Lactobacillus parabrevis, Lactobacillus paracollinoides, Lactobacillus parakefiri, Lactobacillus paraplantarum, Lactobacillus pentosus, Lactobacillus pontis, Lactobacillus reuteri, Lactobacillus rossiae, Lactobacillus salivarius, Lactobacillus siliginis, Lactobacillus sucicola, Lactobacillus vaccinostercus, Lactobacillus vaginalis, Lactobacillus vini, Lactococcus garvieae, or Lactococcus lactis ; and wherein the Faecalibacterium sp., is Faecalibacterium prausnitzii.
5. The method of claim 1 , wherein the bacterial population further comprises Bifidobacterium sp.
6. The method of claim 5 , wherein the Bifidobacterium sp. is Bifidobacterium bifidum, Bifidobacterium pseudolongum, Bifidobacterium saeculare , or Bifidobacterium subtile.
7. The method of claim 1 , wherein the bacterial population comprises less than 20 species of bacteria.
8. The method of claim 1 , wherein the bacterial population is part of a bacterial composition that is not a fecal transplant.
9. The method of claim 1 , wherein the bacterial population is part of a bacterial composition that comprises a pharmaceutically acceptable excipient.
10. The method of claim 1 , wherein the bacterial population is administered orally or rectally.
11. The method of claim 1 , wherein the allergic inflammation is a hypersensitivity, pediatric allergic asthma, allergic asthma, food allergy, or atopic dermatitis.
12. The method of claim 1 , wherein the allergic inflammation is pediatric allergic asthma or inflammatory bowel disease.
13. The method of claim 1 , wherein the subject has at least 1 relative who has been diagnosed with an inflammatory disease.
14. The method of claim 1 , wherein the subject suffers from constipation, diarrhea, bloating, urgency, or abdominal pain.
15. The method of claim 1 , wherein the subject has been administered an antibiotic within the last 1 month.
16. The method of claim 1 , wherein the subject is a neonate.
17. The method of claim 1 , wherein the subject is less than about 24 months old.
18. The method of claim 1 , wherein the subject is between about 2 and about 18 years old.
19. The method of claim 1 , wherein the subject comprises a gastrointestinal microbiome that
(a) has an increased proportion of Streptococcus spp., and Enterococcus spp. compared to a healthy or general population;
(b) has a reduced proportion of Alternaria alternata, Aspergillus flavus, Aspergillus cibarius , and Candida sojae compared to a healthy or general population;
(c) has an increased proportion of Candida albicans and Debaryomyces spp. compared to a healthy or general population;
(d) has a reduced proportion of Bifidobacteria spp., Lactobacillus spp., Faecalibacterium spp. and Akkermansia spp. compared to a healthy or general population;
(e) has a reduced proportion of Malassezia spp. compared to a healthy or general population;
(f) has an increased proportion of Bacterioides spp. or Prevotella spp. compared to a healthy or general population; or
(g) has an increased proportion of Enterococcus fiaecalis, Enterococcus faecium , or Clostridium difficile compared to a healthy or general population.
20. The method of claim 1 , further comprising administering a Cystobacter sp. or a fungal microorganism to the subject.
21. The method of claim 1 , wherein the bacterial population is part of a bacterial composition that is lyophilized.
22. The method of claim 1 , wherein the bacterial population is part of a bacterial composition that is in liquid form.
23. The method of claim 1 , wherein the inflammation is chronic inflammation.
24. The method of claim 1 , wherein the Lactobacillus sp. is Lactobacillus crispatus , and wherein the Faecalibacterium sp., is Faecalibacterium prausnitzii.
25. The method of claim 24 , wherein the bacterial population consists of three bacterial species.
26. The method of claim 1 , wherein the Lactobacillus sp. is Lactobacillus johnsonii , and wherein the Faecalibacterium sp., is Faecalibacterium prausnitzii.
27. The method of claim 26 , wherein the bacterial population consists of three bacteria species.